This page lists the SEC filings reported by Cormorant Asset Management, LP.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2024-04-15 | Cormorant Asset Management, LP | Immuneering Corp | 561,128 | - | EDGAR |
| SC 13G | 2024-03-21 | Cormorant Asset Management, LP | Ventyx Biosciences, Inc. | 3,670,000 | - | EDGAR |
| SC 13G/A | 2024-03-18 | Cormorant Asset Management, LP | Corbus Pharmaceuticals Holdings, Inc. | 2,025,000 | - | EDGAR |
| SC 13G/A | 2024-02-14 | Cormorant Asset Management, LP | 89bio, Inc. | 0 | - | EDGAR |
| SC 13G/A | 2024-02-14 | Cormorant Asset Management, LP | Astria Therapeutics, Inc. | 0 | - | EDGAR |
| SC 13G/A | 2024-02-14 | Cormorant Asset Management, LP | Cabaletta Bio, Inc. | 0 | - | EDGAR |
| SC 13G/A | 2024-02-14 | Cormorant Asset Management, LP | Design Therapeutics, Inc. | 0 | - | EDGAR |
| SC 13G/A | 2024-02-14 | Cormorant Asset Management, LP | Eledon Pharmaceuticals, Inc. | 0 | - | EDGAR |
| SC 13G/A | 2024-02-14 | Cormorant Asset Management, LP | Elevation Oncology, Inc. | 0 | - | EDGAR |
| SC 13G/A | 2024-02-14 | Cormorant Asset Management, LP | Monte Rosa Therapeutics, Inc. | 0 | - | EDGAR |
| SC 13G/A | 2024-02-14 | Cormorant Asset Management, LP | Ambrx Biopharma, Inc. | 8,725,040 | - | EDGAR |
| SC 13G/A | 2024-02-14 | Cormorant Asset Management, LP | Korro Bio, Inc. | 312,052 | - | EDGAR |
| SC 13G/A | 2024-02-14 | Cormorant Asset Management, LP | Longboard Pharmaceuticals, Inc. | 1,027,679 | - | EDGAR |
| SC 13G/A | 2024-02-14 | Cormorant Asset Management, LP | Tarsus Pharmaceuticals, Inc. | 1,600,000 | - | EDGAR |
| SC 13G/A | 2024-02-14 | Cormorant Asset Management, LP | Praxis Precision Medicines, Inc. | 633,345 | - | EDGAR |
| SC 13G/A | 2024-02-14 | Cormorant Asset Management, LP | MARINUS PHARMACEUTICALS, INC. | 3,250,000 | - | EDGAR |
| SC 13G/A | 2024-02-14 | Cormorant Asset Management, LP | ALPINE IMMUNE SCIENCES, INC. | 2,550,000 | - | EDGAR |
| SC 13G/A | 2024-02-14 | Cormorant Asset Management, LP | Olema Pharmaceuticals, Inc. | 2,181,800 | - | EDGAR |
| SC 13G/A | 2024-02-14 | Cormorant Asset Management, LP | Aerovate Therapeutics, Inc. | 0 | - | EDGAR |
| SC 13G | 2024-02-14 | Cormorant Asset Management, LP | Neurogene Inc. | 155,805 | - | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.